中国女人和老外的毛片_少妇激情作爱视频_成人无码区免费AⅤ片在线观看_国产freeXXXX性播放_欧美人与性囗牲恔配的起源

首頁(yè) > 產(chǎn)品目錄 > 信號(hào)通路 > Protein Tyrosine Kinase/RTK > EGFR > 奧希替尼/邁瑞替尼

奧希替尼/邁瑞替尼

ChemLeader 98+%

AZD-9291 (Osimertinib; Mereletinib)

產(chǎn)品編號(hào):CL2211 CAS No.:1421373-65-0 MDLNo: 分子式: C28H33N7O2 分子量: 499.62
規(guī)格 庫(kù)存 目錄價(jià) 會(huì)員專享價(jià) 數(shù)量
250 mg In-stock ¥300.00 登錄后可見(jiàn)
- +
1 g In-stock ¥850.00 登錄后可見(jiàn)
- +

化學(xué)品安全說(shuō)明書(shū)(MSDS)

下載MSDS

質(zhì)檢證書(shū)(COA)

  • 基本信息
  • 相關(guān)文檔
  • 產(chǎn)品詳情
  • 相關(guān)文獻(xiàn)
基本信息
英文名稱 AZD-9291 (Osimertinib; Mereletinib)
中文名稱奧希替尼/邁瑞替尼
CAS號(hào)1421373-65-0
分子式 C28H33N7O2
分子量 499.62
外觀Off-white powder
儲(chǔ)存條件 Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).
產(chǎn)品詳情

Osimertinib, also known as AZD-9291 and Mereletinib, is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin and gut cells, thereby reducing the side effects encountered with currently available medicines. Osimertinib was approved in Nov. 2015 by FDA.

相關(guān)文獻(xiàn)
抱歉,暫時(shí)沒(méi)有相關(guān)文獻(xiàn)
相關(guān)產(chǎn)品
抱歉,暫時(shí)沒(méi)有相關(guān)產(chǎn)品
在線客服
小德
021-58180488
小立
021-58180488
在線服務(wù)時(shí)間: 工作日 9:00-18:00